Orphazyme assumes sp
Orphazyme assumes sponsorship of Phase II/III sIBM trial
15 déc. 2017 09h20 HE | ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
12 déc. 2017 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it has successfully completed a...
2X Oncology Obtains
2X Oncology Obtains Investigational New Drug Application for 2X-111 Glutathione Enhanced PEGylated Liposomal Doxorubicin
08 juin 2017 09h06 HE | 2X Oncology, Inc.
CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
TESARO® logo_RGB_small.png
TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
01 mai 2017 08h30 HE | TESARO, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
Akari Logo (1).jpg
Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
03 janv. 2017 07h00 HE | Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
Axsome Logo.png
Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
03 janv. 2017 07h00 HE | Axsome Therapeutics, Inc.
NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Fate Therapeutics.jpg
Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection
26 janv. 2016 16h36 HE | Fate Therapeutics, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer...
China Food and Drug
China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)
15 juin 2015 16h02 HE | Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration...
FDA Grants Fast Trac
FDA Grants Fast Track Designation to Sucampo's Cobiprostone for Oral Mucositis
07 mai 2015 16h42 HE | Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 7, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine
20 juil. 2011 08h00 HE | Hemispherx Biopharma, Inc.
PHILADELPHIA, July 20, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced it has received U.S. Food Drug Administration (FDA)...